Regulatory transparency in Good Manufacturing Practice (GMP) oversight is entering a period of structural change, driven by increasing expectations from regulators, industry stakeholders, and the broader healthcare ecosystem.
The Therapeutic Goods Administration (TGA) has commenced a public consultation on a proposal to increase transparency regarding Good Manufacturing Practice (GMP) inspection outcomes for manufacturers of pharmaceutical products supplied to Australia.
Software now performs functions that were historically limited to physical medical devices, laboratory instrumentation, or direct clinical assessment.
Commercial pharmaceutical manufacturing within licensed facilities operates under highly controlled regulatory frameworks designed to ensure the safety, quality, efficacy, and consistency of therapeutic goods.